Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
IPO Year: 2013
Exchange: NASDAQ
Website: aeriepharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/29/2022 | $14.00 → $15.25 | Buy → Neutral | Citigroup |
| 8/23/2022 | Buy → Hold | Needham | |
| 8/23/2022 | $30.00 → $15.25 | Overweight → Neutral | Cantor Fitzgerald |
| 2/25/2022 | $22.00 → $14.00 | Buy | Needham |
| 11/5/2021 | $24.00 → $22.00 | Buy | Needham |
| 8/5/2021 | $26.00 → $24.00 | Buy | Needham |
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
15-12G - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
8-K - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. "Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class glaucoma franchise showed strong continued year-over-year growth, in line with our expect
Webinar to be held Friday, September 23, 2022 @ 10 a.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that it will host a Key Opinion Leader (KOL) webinar on Friday, September 23, 2022 from 10:00 a.m. – 11:30 a.m. Eastern Time. The event will feature Dr. Laura Periman, MD, of the Periman Eye Institute, and Dr. John Sheppard, MD, of the Virginia Eye Consultants, who will discuss New Perspectives on Dry Eye Disease (DED), including the Current Landscape, Unmet Medical Needs, and Emerging Treatment Options, including Aerie's investigational TRPM8 agoni
Builds on Alcon's existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770 million in equity value and is expected to be accretive to Alcon's core diluted EPS in 2024 Ad hoc announcement pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced that the compensation committee of Aerie Pharmaceutical's board of directors granted one new employee an award totaling 16,900 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date. This award was made outside of Aerie's stockholder-approved equity incentive plan
Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021 Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022 Aerie Expects to be Cash Flow Break Even During 2024 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the second quarter ended June 30, 2022 and provides its business and pipeline objectives and financial guidance for 2022 and beyond, including its expectation to achieve cash flow break even during 2024. "Aerie delivered a s
AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-3 is the second of three studies in the AR-15512 Registrational Phase 3 Program Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the Phase 3 registrational "COMET-3" study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-3 is the second of three trials in the Phase 3 registrational program for AR-15512. Aerie
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie's financial results and provide a general business update. Details: Date: August 4, 2022 Conference call Time: 5:00 p.m. ET Suggested Dial-in Time: 15 minutes prior to ensure time for any required software download Dial-in Registration:
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced that the compensation committee of Aerie Pharmaceutical's board of directors granted one new employee an award totaling 16,900 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date. This award was made outside of Aerie's stockholder-approved equity incentive plan
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time in New York City, NY. Date: June 10, 2022 Presentation Time: 10:30 a.m. ET Webcast: http://investors.aeriepharma.com Replay Availability: Until September 8, 2022 About Aerie Pharmaceuticals, Inc. Aerie is a pharmaceutic
SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
SC 13G - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
SC 13G - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
SC 13G - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. "Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class glaucoma franchise showed strong continued year-over-year growth, in line with our expect
Builds on Alcon's existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770 million in equity value and is expected to be accretive to Alcon's core diluted EPS in 2024 Ad hoc announcement pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in
Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021 Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022 Aerie Expects to be Cash Flow Break Even During 2024 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the second quarter ended June 30, 2022 and provides its business and pipeline objectives and financial guidance for 2022 and beyond, including its expectation to achieve cash flow break even during 2024. "Aerie delivered a s
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie's financial results and provide a general business update. Details: Date: August 4, 2022 Conference call Time: 5:00 p.m. ET Suggested Dial-in Time: 15 minutes prior to ensure time for any required software download Dial-in Registration:
First Quarter Glaucoma Franchise Net Revenues of $29.8 Million, up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million First Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022. "We continue to execute well on our three strategic pillars to build out
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after the market closes Thursday, May 5, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie's financial results and provide a general business update. Details: Date: May 5, 2022 Conference call Time: 5:00 p.m. ET Suggested Dial-in Time 15 minutes prior to ensure time for any required software download Webcast: http:/
2021 Glaucoma Franchise Net Revenues of $112.1 Million, an Increase of 35% over 2020 Fourth Quarter Glaucoma Franchise Net Revenues of $32.7 Million, up 11% From Third Quarter Guidance of $130 Million to $140 Million in 2022 Glaucoma Franchise Forecasted Net Revenues, up 16% to 25% Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update and financial guidance for 2022. "I am delighted to join Aerie at such an exciting time of our growth trajectory and pleased
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that its fourth quarter and full year 2021 financial results will be released after the market closes on Thursday, February 24, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie's financial results and provide a general business update. Details: Date: February 24, 2022 Conference call Time: 5:00 p.m. ET Suggested Dial-in Time 15 minutes prior to ensure time for any required software download Webcast:
Third Quarter 2021 Net Revenues of $29.3 Million Increased 46% over Third Quarter 2020 Third Quarter 2021 Net Revenue Per Bottle of $89, up 16% over Third Quarter 2020 Phase 3 Studies for AR-15512 and AR-1105 Expected to Begin in the First Half of 2022 Conference Call and Webcast Today, November 4th, at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a general business update. "Our third quarter 2021 results reflect nearly 46 percent growth in net revenues and 26 percent growth in bottle volumes for our U.S. glaucoma franchise compared to the third
Finance executive with a successful track record in capital creation, deployment, and optimization Brings breadth of finance, strategy and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Peter F. Lang will join the Company as Chief Financial Officer, effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee. "I am pleased to welcome Peter to our leadership team," said Raj Kannan, Chief Executive Officer. "His extensive e
Fellowship-trained Ophthalmologist and well-rounded biopharmaceutical executive brings breadth of clinical development, medical affairs, strategy, and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Gary Sternberg, M.D., M.B.A., will join the Company as Chief Medical Officer (CMO), effective March 1, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee. Gary is an Ophthalmologist who is fellowship trained in cornea and external disease
An accomplished leader Brings a depth and breadth of commercial, business development, and portfolio strategy experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief Executive Officer and a director, effective December 20, 2021. "On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie. During the search process, the Board was pleased to interview several strong candidates and Raj rose to the top of the list during the process. Raj brings a track record of building effective organizations and teams, launching and growing products in the U.S. and globally, buildi
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment Erik Pacyniak, Ph.D., D.A.B.T., Director, Toxicology, reporting to Jeff White, Ph.D., D.A.B.T., Aerie's Vice President of Research and Discovery. Dr. Pacyniak will oversee all aspects of nonclinical toxicology and drug disposition for Aerie. He most recently held a related nonclinical safety assessment position at Mycovia Pharmaceuticals, Inc. In connection with his acceptance of the position a
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Carolyn McAuliffe, Senior Director, Communications, reporting to Tad Heitmann, Aerie's Vice President of Marketing. Ms. McAuliffe will be responsible for the development and execution of Aerie's marketing and medical communications activities. She most recently held a related position at Masimo Corporation. In connection with her acceptance of the position as Senior Director, Communications,
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Michael Bradley, Senior Director, Manufacturing, reporting to Site Director, Athlone. Mr. Bradley will be responsible for manufacturing and supply chain operations at Aerie's manufacturing facility in Athlone, Ireland. He most recently held related positions at Norbrook and Zoetis. In connection with his acceptance of the position as Senior Director, Manufacturing, Mr. Bradley will receive a
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Leon J. Atencia, Director of Regulatory Affairs, reporting to Emma Beausang, Aerie's Vice President of Regulatory Affairs. Mr. Atencia will be responsible for clinical regulatory affairs and oversee post-marketing and pharmacovigilance activities. He most recently held a related position at Revance Therapeutics Inc. In connection with his acceptance of the position as Director of Regulatory
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Frank Estrada, Ed.D., as Director, Salesforce Training, reporting to Evan Hockman, Aerie's Vice President of Sales. Dr. Estrada will design, develop and implement the training curriculum for both Territory Sales Managers and the Sales Management Team across the United States. He most recently held a related position at Agendia Inc. In connection with his acceptance of the position as Directo
Citigroup downgraded Aerie Pharma from Buy to Neutral and set a new price target of $15.25 from $14.00 previously
Needham downgraded Aerie Pharma from Buy to Hold
Cantor Fitzgerald downgraded Aerie Pharma from Overweight to Neutral and set a new price target of $15.25 from $30.00 previously
Needham reiterated coverage of Aerie Pharmaceuticals with a rating of Buy and set a new price target of $14.00 from $22.00 previously
Needham reiterated coverage of Aerie Pharmaceuticals with a rating of Buy and set a new price target of $22.00 from $24.00 previously
Needham reiterated coverage of Aerie Pharmaceuticals with a rating of Buy and set a new price target of $24.00 from $26.00 previously
HC Wainwright resumed coverage of Aerie Pharmaceuticals with a rating of Buy
Needham & Company LLC initiated coverage of Aerie Pharmaceuticals with a rating of Buy and set a new price target of $26.00
Aerie Pharmaceuticals (NASDAQ:AERI) brought in sales totaling $36.13 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 38.49%, resulting in a loss of $26.83 million. In Q2, Aerie Pharmaceuticals brought in $33.31 million in sales but lost $19.37 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Aerie P
Aerie Pharmaceuticals (NASDAQ:AERI) reported quarterly losses of $(0.27) per share. This is a 62.5 percent increase over losses of $(0.72) per share from the same period last year. The company reported $36.13 million in sales this quarter. This is a 23.25 percent increase over sales of $29.31 million the same period last year.
Upgrades According to Argus Research, the prior rating for AstraZeneca PLC (NASDAQ:AZN) was changed from Hold to Buy. For the second quarter, AstraZeneca had an EPS of $0.86, compared to year-ago quarter EPS of $0.45. At the moment, the stock has a 52-week-high of $71.70 and a 52-week-low of $55.50. AstraZeneca closed at $66.32 at the end of the last trading period. According to RBC Capital, the prior rating for The Toronto-Dominion Bank (NYSE:TD) was changed from Sector Perform to Outperform. In the third quarter, Toronto-Dominion Bank showed an EPS of $1.62, compared to $1.60 from the year-ago quarter. At the moment, the stock has a 52-week-high of $86.02 and a 52-week-low of $58.64. To
Citigroup analyst Yigal Nochomovitz downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.
Upgrades According to Citigroup, the prior rating for Cyxtera Technologies Inc (NASDAQ:CYXT) was changed from Neutral to Buy. The current stock performance of Cyxtera Technologies shows a 52-week-high of $15.42 and a 52-week-low of $7.09. Moreover, at the end of the last trading period, the closing price was at $7.55. For Centennial Resource Development Inc (NASDAQ:CDEV), Truist Securities upgraded the previous rating of Hold to Buy. For the second quarter, Centennial Resource Dev had an EPS of $0.60, compared to year-ago quarter EPS of $0.03. At the moment, the stock has a 52-week-high of $9.70 and a 52-week-low of $5.08. Centennial Resource Dev closed at $7.74 at the end of the last
According to data from Benzinga Pro, during Q2, Aerie Pharmaceuticals's (NASDAQ:AERI) reported sales totaled $33.31 million. Despite a 46.03% increase in earnings, the company posted a loss of $19.37 million. Aerie Pharmaceuticals collected $29.84 million in revenue during Q1, but reported earnings showed a $35.89 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE
Truist Securities analyst Gregory Fraser downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Hold.
HC Wainwright & Co. analyst Oren Livnat downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.
Gainers Windtree Therapeutics, Inc. (NASDAQ:WINT) shares jumped 55.2% to close at $0.70 on Tuesday after the company announced it has entered into a global licensing agreement for the development and commercialization of KL4 surfactant and AEROSURF. The company may receive up to $78.9 million in milestones. Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) jumped 53% to close at $1.49. Reviva Pharmaceuticals recently posted Q2 loss of $0.29 per share. Neptune Wellness Solutions Inc. (NASDAQ:NEPT) climbed 53% to close at $3.06. Indonesia Energy Corporation Limited (NYSE:INDO) shares gained 49.4% to close at $11.50 after gaining over 6% on Monday. China Index Holdings Limited (NASDAQ
U.S. stocks closed mostly lower with the Dow Jones dropping more than 150 points on Tuesday. Here is the list of some big stocks moving higher in the previous session. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) shares jumped 36% to close at $15.16. Alcon AG (NYSE:ALC) agreed to acquire Aerie Pharmaceuticals for $15.25 per share, valuing Aerie at about $770 million. FiscalNote Holdings, Inc. (NASDAQ:NOTE) gained 19.3% to close at $10.32. FiscalNote Holdings recently posted a Q2 loss of $3.06 per share. AMC Entertainment Holdings, Inc. (NYSE:APE) gained 17% to close at $7.02. Verve Therapeutics, Inc. (NASDAQ:VERV) rose 12.3% to settle at $36.77. Verve Therapeutics announced new preclinica